Literature DB >> 2514421

Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor.

G Pfliegler1, Z Boda, J Hársfalvi, M Flóra-Nagy, B Sári, K Pecze, K Rak.   

Abstract

A 47 year old woman is reported who had life-threatening bleeding due to the spontaneous development of factor VIII:C inhibitor. Cyclosporin combined with prednisone resulted in a full recovery and complete elimination of antibody even when other therapeutic facilities failed to be effective.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2514421      PMCID： PMC2429330          DOI： 10.1136/pgmj.65.764.400

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  10 in total

1.  An acquired inhibitor to factor VIIIC in a non-hemophiliac: twenty years of observation and characterization.

Authors:  M C Coots; H I Glueck
Journal:  Am J Hematol       Date:  1987-04       Impact factor: 10.047

2.  Acquired factor VIII inhibitor associated with lung abscess.

Authors:  P S Ganly; J D Isaacs; M A Laffan; C Haslett; J M Hows
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-03

3.  Evaluation of the cuticle bleeding time in canine haemophilia A.

Authors:  M I Pijnappels; E Briët; G T van der Zwet; R Huisden; N H van Tilburg; F Eulderink
Journal:  Thromb Haemost       Date:  1986-02-28       Impact factor: 5.249

4.  Cyclosporin. Mechanism of action: in vitro studies.

Authors:  A D Hess; P M Colombani
Journal:  Prog Allergy       Date:  1986

5.  The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.

Authors:  M W Hilgartner; G L Knatterud
Journal:  Blood       Date:  1983-01       Impact factor: 22.113

6.  Study of platelet agglutination induced by the antibiotics of the vancomycin group: ristocetin, ristomycin, actinoidin and vancomycin.

Authors:  Z Boda; N O Solum; F Sztaricskai; K Rak
Journal:  Thromb Haemost       Date:  1979-12-21       Impact factor: 5.249

7.  Cyclosporine: progress, problems, and perspectives.

Authors:  C T Van Buren
Journal:  Surg Clin North Am       Date:  1986-06       Impact factor: 2.741

8.  A patient with a spontaneous factor VIII:C autoantibody: successful treatment with cyclosporine.

Authors:  H C Hart; R J Kraaijenhagen; J A Kerckhaert; G Verdel; M Freen; A van de Wiel
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

9.  A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.

Authors:  D Green; K Lechner
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

10.  Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.

Authors:  J M Lusher; S S Shapiro; J E Palascak; A V Rao; P H Levine; P M Blatt
Journal:  N Engl J Med       Date:  1980-08-21       Impact factor: 91.245
  10 in total
  2 in total

Review 1.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

2.  Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.

Authors:  Zahra Rezaieyazdi; Hassan Mansouritorghabeh
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.